Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

iCLAS™ for Persistent Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04061603
Recruitment Status : Recruiting
First Posted : August 20, 2019
Last Update Posted : September 20, 2021
Sponsor:
Information provided by (Responsible Party):
Adagio Medical

Brief Summary:
Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)

Condition or disease Intervention/treatment Phase
Persistent Atrial Fibrillation Device: Adagio AF Cryoablation System (iCLAS™) Not Applicable

Detailed Description:
A staged pre-market, single-arm, clinical study designed to collect acute and long-term safety and efficacy data for the Adagio AF Cryoablation System (iCLAS™). Patient population will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure. Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment at one, three, six, and twelve months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Symptomatic persistent atrial fibrillation that failed at least one class I or Class III AAD with no prior history of ablation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: iCLAS™ for Persistent Atrial Fibrillation
Actual Study Start Date : December 9, 2019
Estimated Primary Completion Date : December 9, 2021
Estimated Study Completion Date : December 9, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: iCLAS Ablation
Ablation of the left and right atrium with the Adagio Medical iCLAS System
Device: Adagio AF Cryoablation System (iCLAS™)
Endovascular ablation of the left and right atrium




Primary Outcome Measures :
  1. Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure. [ Time Frame: 12-months ]

    MAEs include any of the following:

    • Death
    • Myocardial infarction
    • Cardiac perforation/pericardial tamponade
    • Cerebral infarct or systemic embolism
    • Major bleeding requiring transfusion of blood products
    • Mitral or tricuspid valve damage
    • Symptomatic pulmonary vein stenosis
    • Severe (≥ 70%) pulmonary vein stenosis
    • Permanent phrenic nerve injury
    • Access site complications requiring pharmacological or surgical intervention
    • Atrio-esophageal fistula
    • Pericarditis
    • Heart block requiring a permanent pacemaker
    • Vagal nerve injury with GI dysmotility
    • Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as "probably or definitely related" to the Adagio System

  2. Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT). [ Time Frame: 12-months ]
    The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.


Secondary Outcome Measures :
  1. Recording and analysis of all identified SAEs and SADEs through 12-months post-procedure. [ Time Frame: 12-months ]

    Events will be sub-stratified based on time to event as follows:

    • Early onset (procedure through 7-days post-ablation)
    • Peri-procedure (> 7-days through 30-days post-ablation)
    • Late onset (>30-days post ablation)

  2. Analysis of the proportion of subjects with acute procedural (ablation) success [ Time Frame: 20-minutes following last ablation ]
    Documentation of pulmonary vein isolation and posterior wall isolation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

IC1 Male or female between the ages of 18 and 80 years

IC2 Currently scheduled for an ablation of symptomatic, PsAF defined as continuous AF that is sustained > 7-days and ≤ 12 months and documented by the following: a. Physician's note indicating continuous AF > 7 days and ≤ 12 months, AND b. One of the following: i. 24-hour Holter within 180 days of enrollment showing continuous AF, OR ii. Two electrocardiograms from any forms of rhythm monitoring (e.g., 12-lead ECGs or single lead ECGs) completed ≥ 7 days apart within 180 days of enrollment.

IC3 Refractory to at least one class I or III AAD. (Refractory defined as not effective, not tolerated or not desired)

IC4 Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study

IC5 Willingness and ability to give an informed consent

EXCLUSION CRITERIA

EC 1 In the opinion of the Investigator, any known contraindication to an atrial ablation, TEE, or anticoagulation. Including, but not limited to, the identification of any atrial thrombus or evidence of sepsis

EC 2 Any duration of continuous AF lasting longer than 12-months

EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT

EC 4 Atrial fibrillation secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause

EC 5 Structural heart disease as described below:

  1. Left ventricular ejection fraction (LVEF) < 40% based on most recent TTE
  2. Left atrial size > 55 mm (parasternal long axis view) documented within 6-months of screening
  3. NYHA Class III or IV heart failure documented within the previous 12-months
  4. An implanted pacemaker or ICD
  5. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG),
  6. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve
  7. Interatrial baffle, closure device, patch, or PFO occluder
  8. Presence of a left atrial appendage occlusion device
  9. Presence of any pulmonary vein stenting devices
  10. Coronary artery bypass graft (CABG) or PTCA procedure within 6 months prior to procedure
  11. Unstable angina or ongoing myocardial ischemia
  12. Myocardial infarction within the previous six (6) months prior to procedure
  13. Moderate or severe mitral insufficiency or stenosis based on most recent TTE
  14. Atrial myxoma
  15. Significant congential anomaly

EC 6 BMI > 40

  • BMI >35 and no prior sponsor approval into the study

EC 7 Any previous history of cryoglobulinemia

EC 8 History of blood clotting or bleeding disease

EC 9 History of severe COPD requiring steroid use in the previous 12-months

EC 10 History of severe sleep apnea (AHI > 30) not currently treated with a CPAP machine or other mechanical device

EC 11 Any prior history of documented cerebral infarct including recent TIA (within one year) or systemic embolism (excluding a post-operative DVT)

EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis

EC 13 Pregnant or lactating (current or anticipated during study follow-up)

EC 14 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study

EC 15 Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center, COVID-19 related concerns)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04061603


Contacts
Layout table for location contacts
Contact: Erum S Shaikh 949-348-1188 eshaikh@adagiomedical.com
Contact: Nabil Jubran 949-348-1188 ext 207 njubran@adagiomedical.com

Locations
Show Show 20 study locations
Sponsors and Collaborators
Adagio Medical
Layout table for additonal information
Responsible Party: Adagio Medical
ClinicalTrials.gov Identifier: NCT04061603    
Other Study ID Numbers: CS-200
First Posted: August 20, 2019    Key Record Dates
Last Update Posted: September 20, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes